Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00968916
First received: August 28, 2009
Last updated: September 18, 2014
Last verified: September 2014
  Purpose

Primary objective: To determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of AVE8062 administered every 3 weeks in patients with advanced solid tumors.

Secondary objectives:

  • To assess the overall safety profile of the drug.
  • To characterize the pharmacokinetic profile of AVE8062 and its active metabolite RPR 258063.
  • To evaluate anti-tumor activity of the drug.

Condition Intervention Phase
Solid Tumor
Drug: ombrabulin (AVE8062)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With AVE8062 Administered as a 30-minute Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Dose limiting toxicity at Cycle 1 [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Global safety profile based on treatment emergent adverse events, serious adverse events, and laboratory abnormalities [ Time Frame: all cycles ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic parameters of AVE8062: Cmax, AUC, CL, Vss, and t1/2 [ Time Frame: Day 1 and 2 of Cycle 1, and day 1 of subsequent cycles ] [ Designated as safety issue: No ]
  • Pharmacokinetic parameters of AVE8062's active metabolite RPR258063: Cmax, AUC, t1/2, and Metabolic ratio [ Time Frame: Day 1 and 2 of Cycle 1, and day 1 of subsequent cycles ] [ Designated as safety issue: No ]
  • Objective tumor response as defined by the Response Evaluation Criteria in Solid Tumors in evaluable patients [ Time Frame: from patient informed consent to end of treatment ] [ Designated as safety issue: No ]

Enrollment: 15
Study Start Date: September 2009
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1

Level 1:

15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal

Level 2:

25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal

Level 3:

35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal

Level 4:

50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal

Drug: ombrabulin (AVE8062)

Pharmaceutical form: injection solution

Route of administration: intravenous infusion


Detailed Description:

The duration of the study for each patient will include an up to 4-week screening phase, 21-day study treatment cycles, an end of treatment visit and a follow-up period.

  Eligibility

Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced solid tumor that has become refractory to conventional treatment or for which no standard therapy exists.
  • Patients with signed and dated Institutional Review Board (IRB)-approved patient informed consent form (ICF) prior to enrollment in the study.

Exclusion Criteria:

  • Eastern Cooperative Oncology Group performance status > or = 2.
  • Life expectancy of less than 12 weeks.
  • Concurrent treatment with any other anticancer therapy, including chemotherapy, immunotherapy, radiotherapy, targeted therapy, gene therapy, or patients planning to receive these treatments during the study.
  • Absence of histologically or cytologically proven cancer.
  • Male patients who do not agree with contraception. Absence of negative serum/urinary pregnancy test within the 7 days prior to the enrollment in the study for female patients with childbearing potential. Patients must be post-menopausal, surgically sterile, or using "effective contraception" (the definition of "effective contraception" will be based on the judgment of the investigator).
  • Washout period of less than 28 days from prior antitumor therapy (chemotherapy, targeted agents, immunotherapy and radiotherapy) or any investigational treatment, except for nitrosoureas, mitomycin which may not be used up to 42 days prior to the first cycle. No washout period is required for hormonal therapy, however, it must be discontinued before the first cycle.
  • Not recovered from all previous therapies (radiation, surgery, and medications). Adverse events related to previous therapies must be National Cancer Institute Common Terminology Criteria grade < or = 1 (or alopecia < or = grade 2) at screening or returned to the subject's baseline prior to their most recent previous therapy.
  • Symptomatic brain metastases and carcinomatous leptomeningitis.
  • Other serious illness or medical conditions:

    • Existence of significant neurologic or psychiatric disorders impairing the ability to obtain consent.
    • Active infection.
    • Other serious illness not controlled by adequate treatment.
  • Inadequate organ function including:

    • Absolute neutrophils counts<1.5 x 10^9/L
    • Platelets counts<100 x 10^9/L
    • Hemoglobin<9.0 g/dL (without red blood cells transfusion during 28 days prior to the test)
    • Calculated creatinin clearance<60 ml/min
    • Total bilirubin > or = 1.5 mg/dL
    • Alanine aminotransferase/aspartate aminotransferase>1.5 times the upper normal limits of the institutional norms.
    • Alkaline phosphatase (AP)>2.5 times the upper normal limits of the institutional norms. An increase of AP up to grade 2 would be accepted only if this increase is related to the presence of bone metastases. Bone specific isoenzyme AP should be greater than the pathological limit defined by the manufacturer as a sign of bone metastases.
  • Documented medical history of myocardial infarction, documented angina pectoris, arrhythmia especially severe conduction disorder such as second or third degree atrio-ventricular block, stroke, or history of arterial or venous thrombo-embolism within the past 180 days requiring anticoagulants.
  • Patient with a left ventricular ejection fraction<50% by echocardiography.
  • Patient with a baseline QTc interval of >0.45, or family history of Long QT Syndrome
  • Patient with uncontrolled hypertension and patient with organ damage related to hypertension such as left ventricular hypertrophy or grade 2 ocular funduscopic changes or kidney impairment.
  • Patient with growing vessel disease (eg age-related macular degeneration, diabetic retinopathy, rheumatoid arthritis), or ongoing wound healing process. Patient should be enrolled in the study at least 28 days after surgery.
  • 12-lead Electrocardiogram: ST- and T-wave changes suggesting ischemia
  • Hypertension defined as systolic blood pressure (BP)>140 mmHg or diastolic BP>90 mmHg on two repeated measurements at 30 minutes intervals.
  • Patient with one or more episodes of ventricular tachycardia with 3 or more consecutive premature beats, with a frequency > or = 180 beats/min.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00968916

Locations
Japan
Sanofi-Aventis Investigational Site Number 392002
Osaka Sayama-Shi, Japan
Sanofi-Aventis Investigational Site Number 392001
Sunto-Gun, Japan
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

No publications provided by Sanofi

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT00968916     History of Changes
Other Study ID Numbers: TED10967
Study First Received: August 28, 2009
Last Updated: September 18, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on October 01, 2014